Pharma Future Through Digital Innovation

Digital capabilities only create value when tied to measurable patient outcomes, making technology as one element within a broader healthcare ecosystem, says Takeda's Victor Villalba. Takeda is focusing on R&D, therapy design, plasma-derived therapies, and supply chain quality , while strengthening Mexico's role as a global capability hub. 

Takeda is pushing digital transformation as a means to strengthen patient care, not as an end in itself, says Victor Villalba, GDM Site Lead Mexico, Takeda. Speaking at the Mexico Health Summit 2026, Villalba positioned technology as one component within a broader ecosystem that includes regulation, process change, and cross-sector collaboration, rather than a standalone objective for the pharmaceutical industry.

"Integrating new health technologies and building digital capabilities only adds value when applied to real care outcomes. Digitalization for digitalization's sake adds little value," says Villalba. He adds that innovation is not the product of a single breakthrough idea but a methodical, sustained process built across the company's business units, including gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines.

Villalba frames Takeda's approach around four core value areas: R&D aimed at reducing diagnostic and treatment timelines, therapy design that eases the patient journey, plasma-derived therapy production, and supply chain quality that ensures treatments reach patients on time and in the right condition. He notes that all four areas are guided by patient-centricity as the company's primary decision-making criterion, ahead of commercial considerations.

Takeda operates more than 20 manufacturing sites and two specialized biopharmaceutical R&D centers globally, with a presence in more than 80 countries. In Mexico, the company has invested in one of its three global capability development hubs, citing geographic and time zone alignment as well as local talent in software development and data science as key factors behind the decision. Villalba highlights that Takeda employees have logged more than 30,000 hours of training in digital skills and emerging technologies, underscoring the company's effort to build internal capacity rather than treat digitalization as an isolated technology purchase.

The company marks 245 years of global operations and 60 years in Mexico, a tenure Villalba links to consistent trust and reputation management within the biopharmaceutical sector. He argues that any technology deployment must account for the full patient ecosystem, including hospitals, physicians, regulators, and family support systems, warning that narrowly scoped digital solutions risk producing limited results.

Takeda's emphasis on applied, outcome-driven digitalization echoes a broader shift underway across Mexico's pharmaceutical sector. Sanofi's MX$665 million investment in clinical research in immunology, oncology, vaccines, and chronic disease treatment similarly reflects how AI and data-driven research are becoming central to accelerating drug development timelines in the country, rather than serving as peripheral initiatives.

The push also aligns with growing institutional momentum around digital health infrastructure. Hospital General de México's launch of an AI research center integrating data science and engineering into clinical and administrative applications signals a broader move from isolated digital pilots toward permanent infrastructure.

Villalba's remarks reinforce the theme that talent development is inseparable from digital transformation. He points to Takeda's capability centers as a mechanism for building software engineering, data science, and agile transformation expertise locally, positioning Mexico's talent pool as a driver of the company's broader digital strategy rather than a downstream beneficiary of it.